FindTrial
Sign In

Combined Interventional Therapy for Hepatocellular Carcinoma in the patients with Child-Turcotte-Pugh B and C.

Combined Interventional Therapy for Hepatocellular Carcinoma in the patients with Child-Turcotte-Pugh B and C.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-10000853
Enrollment
Unknown
Registered
2010-04-27
Start date
2008-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

treatment group:TAE+PSE+RFA
control:TAE

Sponsors

Beijing You-An Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. liver cancer Association of anti-cancer association in China in 2001 revised clinical diagnostic criteria of primary liver cancer and clinical staging; 2. Chinese Medical Association Guide advised HBV infection in 2005; 3. Child--Turcotte-Pugh B and C-class; 4. aged 20-80 years old, either sex; 5. preoperative ALT = <200U/L, TBIL = <68umol/l; 6. WBC = <3E +09/L, PLT = <60E + 09/L; 7. intrahepatic tumor number = <5, the maximum diameter =<5cm, without tumor thrombus in portal vein and branches, no extrahepatic tissues and lymph node metastasis; 8. No serious organic disease of other organs; 9. signed informed consent.

Exclusion criteria

Exclusion criteria: diffused Hepatocelluar carcinoma AC

Design outcomes

Primary

MeasureTime frame
size of tumor;—

Secondary

MeasureTime frame
one year survival;—

Countries

China

Contacts

Public ContactJia-sheng Zheng
zhengjiasheng6@163.com+86 13901355160

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026